lenalidomide has been researched along with HTLV-I Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Challen, G; Harding, JC; Kim, Y; MacLeod, AR; Olson, SL; Ratner, L; Rauch, DA; Sundaramoorthi, H; Zhou, T | 1 |
| Hasegawa, A; Ishizawa, M; Kannagi, M; Katagiri, K; Kondo, N; Masuda, T; Nagano, Y; Yoneda, T | 1 |
2 other study(ies) available for lenalidomide and HTLV-I Infections
| Article | Year |
|---|---|
Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Gene Products, tax; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Interferon Regulatory Factors; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Mice; Oligonucleotides, Antisense; Signal Transduction; Thionucleotides | 2020 |
Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.
Topics: Antiviral Agents; Cell Line; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Lenalidomide; Microbial Sensitivity Tests; Thalidomide | 2021 |